HOME >> BIOLOGY >> NEWS
NIAMS funds multicenter study of surgical vs. nonsurgical treatment of back pain

Surgical versus nonsurgical treatment of three back disorders will be studied in 1,450 patients at 11 medical centers with funds awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH). Researchers at these centers will compare the two treatment approaches in patients who have a herniated (bulging) lumbar disc, spinal stenosis (narrowing of the canal through which the spinal cord passes) or degenerative spondylolisthesis, where a vertebra in the spine slips forward out of place. This project is expected to have a major impact on clinical practice and on the cost of medical services for persons with one of the three back disorders.

The 5-year study, which will cost more than $13.5 million, is being performed under the direction of James N. Weinstein, D.O., M.S., professor in the Department of Community and Family Medicine, Center for the Evaluative Clinical Sciences, and professor of surgery at Dartmouth Medical School. Participating centers include: Case Western Reserve University (Cleveland, Ohio), Dartmouth Medical School (Hanover, N.H.), Emory Spine Center (Decatur, Ga.), the Hospital for Special Surgery (New York, N.Y.), Rothman Institute (Philadelphia, Pa.), Nebraska Spine Surgeons, PC (Omaha, Neb.), Rush-Presbyterian-St. Luke Medical Center (Chicago, Ill.), University of California (San Francisco, Calif.), The Hospital for Joint Diseases (New York, N.Y.), Washington University (St. Louis, Mo.) and William Beaumont Hospital (Royal Oak, Mich.).

Patients enrolled in the study will be randomly assigned to either surgical or nonsurgical treatment. In the nonsurgical group, treatments will be prescribed according to the diagnosis and duration of the condition. Among the nonsurgical treatments included in the study are: 1-3 days of bed rest, physical therapy, home exercise, epidura
'"/>

Contact: Judith Wortman
wortmanj@exchange.nih.gov
301-496-8190
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
23-Sep-1999


Page: 1 2

Related biology news :

1. NIAMS funds the North American Spondylitis Consortium
2. NIGMS funds Center for Quantitative Biology
3. $5 million grant funds partnership, studies of minority-based issues in reproductive health
4. NIH funds new Boston College-Boston University study of B-1a cell associated with leukemia
5. NSF funds summer research program abroad for undergraduates at UC San Diego
6. Research to create lung-cancer blood tests receives $3.4M in Pennsylvania tobacco settlement funds
7. The DFG funds a new research vessel
8. NIH funds Breast Cancer and the Environmental Research Center at Fox Chase Cancer Center
9. Grant funds research to develop tissue-engineered solutions for heart disease
10. Stuart research funds generating dividends for veterinary medicine
11. Grant funds research to develop microbicide barrier to HIV

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2017)... YORK , Feb. 2, 2017  EyeLock LLC, ... released a new white paper " What You Should ... The problem of ensuring user authenticity is a growing ... the authentication of users. However, traditional authentication schemes such ... Biometric authentication offers an elegant solution ...
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... LOS ANGELES , Feb. 16, 2017 /PRNewswire/ ... CAPR ), a clinical-stage biotechnology company developing first-in-class ... today announced that it has elected to terminate ... to natriuretic peptide receptor agonists, including Cenderitide. ... a strategic move as we prioritize our efforts ...
(Date:2/16/2017)... PALM BEACH, Florida , February 16, 2017 ... vastly improving with the infusion of innovative telemedicine ... patient monitoring services that are experiencing a boom ... evolve with the advancement of technologies, services and ... Technologies Inc. (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, ...
(Date:2/16/2017)... Feb. 16, 2017  Dermata Therapeutics, LLC, a ... treat a variety of dermatological diseases, today announced ... financing and entered into a $5 million credit ... to use the capital for general corporate purposes ... in the treatment of serious diseases treated by ...
(Date:2/16/2017)... , ... February 16, 2017 , ... ... case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed the procedure on ... performed on a 55-year-old practicing female physician suffering from degenerative disc disease with ...
Breaking Biology Technology:
Cached News: